Predict your next investment

Corporation
HEALTHCARE | Drug Development
kbibiopharma.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$9.6M

About KBI Biopharma

KBI Biopharma (KBI) is a development and contract manufacturing organization serving the biopharmaceutical industry. The company helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services in an agile, client-friendly partnering environment. Clients include global pharmaceutical and biotechnology companies and academic/non-profit organizations.

KBI Biopharma Headquarter Location

1101 Hamlin Road

Durham, North Carolina, 27704,

United States

919-479-9898

Latest KBI Biopharma News

Global Cell Therapy Manufacturing Market Report 2021, Featuring Key Players KBI Biopharma, Waisman Biomanufacturing, Merck and Thermo Fisher Scientific

Nov 26, 2021

The global cell therapy manufacturing market is projected to grow in the forecast period, 2022-2026 with an impressive CAGR. The market growth can be attributed to rapid growth of biopharmaceutical industries, all over the globe. The development of the advancing therapies and transforming paradigm of several life threatening diseases is driving the growth of the global cell therapy manufacturing market in the upcoming five years. The ongoing COVID-19 pandemic has played a significant role in growth of the global cell therapy manufacturing market. The healthcare industry was involved with the extensive research and technological advancements that leads to the advanced medicine and treatment facilities for the patients. The urgent need for effective therapies as well as vaccine against the infection supported the exponential growth in the market in the past two years. The market is expected to sustain similar growth in future five years on the same factor. Although the research is consistently growing, the expertise in the sector is limited and the lack of specialized infrastructure to produce cell therapies and various product development may cause a mild restraint on the future growth of the market. The global cell therapy manufacturing market is segmented on the basis of therapy, source of cell, scale of operation, source, application, end user, competitional landscape, and regional distribution. Based on basis of therapy, the market is further bifurcated into T-cell therapies, dendritic cell therapies, tumor cell therapies, and stem cell therapies. Stem cell therapy is anticipated to hold the largest shares of the market and dominate the segment in the next five years on the account of rising research and development in the area. Stem cells therapy are utilized for the cures of various chronic diseases and the consistent efforts to provide the best available treatment to the patients. Additionally, growing number of ongoing clinical trials and increased stem cell therapy products in the market is aiding the growth of the global cell therapy manufacturing market in the upcoming five years. Rising FDA approvals, and dedicated biopharma companies for the consistent evolution of the cell therapies are also substantiating the growth of the global cell therapy manufacturing market in the next five years. Years considered for this report: Historical Years: 2016 - 2019

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing KBI Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KBI Biopharma is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

KBI Biopharma Patents

KBI Biopharma has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Genetics
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/16/2009

7/28/2015

Biomaterials, Chemical processes, Oil shale technology, Biomedical engineering, Chemical equipment

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/16/2009

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/28/2015

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Biomaterials, Chemical processes, Oil shale technology, Biomedical engineering, Chemical equipment

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.